Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
Cancer|June 29, 2016
Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496)Stefan K Barta, Hailun Li, Howard S Hochster, et al.
Arthritis Care & Research|September 30, 2024
Racial Disparities and Achievement of the Low Lupus Disease Activity State: A CARRA Registry StudyWilliam Daniel Soulsby, Rebecca Olveda, Jie He, et al.
American Journal of Hematology|October 29, 2014
Extramedullary Waldenström macroglobulinemiaRanjit Banwait, Yosra Aljawai, Joseph Cappuccio, et al.
The Journal of Clinical Investigation|March 5, 2013
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progressionAldo M Roccaro, Antonio Sacco, Patricia Maiso, et al.
British Journal of Haematology|December 18, 2012
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational studyRachel Rosovsky, Fangxin Hong, Deanna Tocco, et al.
BMJ Open Respiratory Research|July 1, 2021
Air quality, Environment and Respiratory Outcomes in Bronchopulmonary Dysplasia, the AERO-BPD cohort study: design and adaptation during the SARS-CoV-2 pandemicHana B Ruran, Gary Adamkiewicz, Amparito Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Fangxin Hong, Swaminathan Padmanabhan, et al.
Mayo Clinic Proceedings|July 13, 2004
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activityPaul Richardson, Robert Schlossman, Sundar Jagannath, et al.
Blood|January 5, 2013
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemiaIrene M Ghobrial, Federico Campigotto, Timothy J Murphy, et al.
British Journal of Haematology|April 3, 2015
Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantationMathew Weinstock, Yosra Aljawai, Elizabeth A Morgan, et al.
Pageof 8